Serum exosome-derived galectin-10 for diagnosis and identification of disease phenotype and endotype
A method for assessing platinum drug resistance through the detecting of RNA modifications encapsulated within extracellular vesicles (EVs) released from ovarian cancer tissue
Identification of COVID-19 severity marker genes for each cell type by single-cell RNA sequencing of patient and healthy population samples
Highly accurate cancer diagnosis by immunological testing of SDF4 in blood
Analysis programs and devices that enable cancer/cancer-subtypes prediction based on transcriptome analysis using next-generation sequencers(NGS)/ microarray.
Mass spectrometry (MS) analysis program and equipment for cancer detection and prediction of cancer subtypes based on urinary metabolomics analysis using MS.
Selection of oocytes using follicular fluid miRNA markers that correlate with pregnancy outcome can provide fertility treatments with high pregnancy rates
Measurement of Two Markers in urine samples enables colorectal cancer risk diagnosis with sensitivity: 94.3%, specificity: 63.4%, AUC=0.870.
Gene copy number profile of extracellular vesicles in body fluid to determine the sensitivity of ovarian cancer to the anticancer drug PARP inhibitors.
Diagnostic biomarkers for stratification of COVID-19 patients and prediction of prognostic severity.
Biomarkers for prediction and diagnosis of interstitial pneumonia, a side effect of cancer treatment with immune checkpoint inhibitors
POI could be diagnosed by detecting autoantibody reacting to POTE proteins expressing in ovarian tissue
Screening test for early stage gastric cancer, esophageal cancer and colorectal cancer patients by measuring urine miRNAs specific to each cancer.